3 As neuroscientist Elie Gottlieb, PhD, who was not involved in the study, notes, Where this study adds the most value is in reminding the field that a treatment strategy anchored exclusively to weight losswhether through GLP-1 receptor agonists, bariatric surgery, or lifestyle interventionwill leave a substantial portion of the OSA population without a clear therapeutic path.' This is where a new opportunity lies
Confocal microscopy (Leica, Wetzlar, Hesse, Germany) was used to visualize the mitochondrial structure
For patients in New Windsor, exploring weight management solutions like Zepbound or other insurance-covered medications through platforms such as Klinic becomes sensible
Retatrutide expands that framework by adding glucagon receptor activity, allowing scientists to explore additional pathways and interactions
That context is educational background for a provider conversation
PubMed record Chang CH, et al